Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Targeting MUC1-C sensitizes colorectal cancer cells to BRAF inhibitor

ABSTRACT: Targeting MUC1-C sensitizes colorectal cancer cells to BRAF inhibitor

PROVIDER: PRJNA890903 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR21918700_1.fastq.gz	Fastqsanger.gz
	SRR21918700_2.fastq.gz	Fastqsanger.gz
	SRR21918701_1.fastq.gz	Fastqsanger.gz
	SRR21918701_2.fastq.gz	Fastqsanger.gz
	SRR21918702_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 24

Similar Datasets

Targeting MUC1-C sensitizes colorectal cancer cells to BRAF inhibitor

Project description:BRAF mutant colorectal cancer has a poor prognosis and gets resistant to BRAF inhibitors quickly. This study aims to clarify the mechanism of resistance to BRAFi. We found MCU1-C is overexpressed in BRAF mutant colorectal cancer and targeting MUC1-C genetically and pharmacologically sensitized Colorectal cancer cells to BRAF inhibitor. This finding suggests that MUC1-C could be a new therapeutic target for BRAF mutant colorectal cancer.

2022-11-30 | GSE215849 | GEO

BRAF paradox breakers PLX8394 and PLX7904 comparison to BRAF inhibitor PLX4720 effect on BRAF V600Ε mutant colorectal adenocarcinoma cells

Project description:BRAF paradox breakers PLX8394 and PLX7904 comparison to BRAF inhibitor PLX4720 effect on BRAF V600Ε mutant colorectal adenocarcinoma cells

| PRJEB38086 | ENA

Expression of BRAF inhibitor resistant colon cancer lines

Project description:Colon cancer cell lines with partial sensitivity to the BRAF inhibitor PLX4720 were grown in increasing concentration of the drug to develop acquired resistance. Gene expression was performed for comparison of the resistant clones to the parental lines. Colon cancer cell lines with partial sensitivity to the BRAF inhibitor PLX4720 were grown in increasing concentration of the drug to develop acquired resistance. Gene expression was performed for comparison of the resistant clones to the parental lines.

2012-09-15 | E-GEOD-34299 | biostudies-arrayexpress

Epigenetic reprogramming in adaptive drug resistance to BRAF inhibitor therapy

Project description:The development of drug resistance is a major limiting factor to the efficacy of BRAF inhibitor therapy for melanoma. The goal of this study was to identify and characterize pathways that contribute to adaptive drug resistance to BRAF inhibitors.

2021-12-31 | GSE156302 | GEO

MUC1-C is necessary for SHP2 activation and BRAF inhibitor resistance in BRAF(V600E) mutant colorectal cancer.

Project description:Colorectal cancers (CRCs) harboring the BRAF(V600E) mutation are associated with aggressive disease and resistance to BRAF inhibitors by feedback activation of the receptor tyrosine kinase (RTK)→RAS→MAPK pathway. The oncogenic MUC1-C protein promotes progression of colitis to CRC; whereas there is no known involvement of MUC1-C in BRAF(V600E) CRCs. The present work demonstrates that MUC1 expression is significantly upregulated in BRAF(V600E) vs wild-type CRCs. We show that BRAF(V600E) CRC cells are dependent on MUC1-C for proliferation and BRAF inhibitor (BRAFi) resistance. Mechanistically, MUC1-C integrates induction of MYC in driving cell cycle progression with activation of the SHP2 phosphotyrosine phosphatase, which enhances RTK-mediated RAS→ERK signaling. We demonstrate that targeting MUC1-C genetically and pharmacologically suppresses (i) activation of MYC, (ii) induction of the NOTCH1 stemness factor, and (iii) the capacity for self-renewal. We also show that MUC1-C associates with SHP2 and is required for SHP2 activation in driving BRAFi-induced feedback of ERK signaling. In this way, targeting MUC1-C in BRAFi-resistant BRAF(V600E) CRC tumors inhibits growth and sensitizes to BRAF inhibition. These findings demonstrate that MUC1-C is a target for the treatment of BRAF(V600E) CRCs and for reversing their resistance to BRAF inhibitors by suppressing the feedback MAPK pathway.

| S-EPMC10408991 | biostudies-literature

protein levels in BRAF inhibitor resistance melanoma cells treated with PF3758309

Project description:11 BRAF inhibitor resistance melanoma cells were treated with PAK inhibitor PF3758309 for 48 hr, the cell lysis were analyzed by RPPA profiling by protein array (RPPA)

2017-07-31 | GSE96753 | GEO

Transcriptomic profiling of melanomas treated with BRAF inhibitor

Project description:Transcriptomic profiling of melanomas treated with BRAF inhibitor

| PRJNA678300 | ENA

Expression data of BRAF inhibitor resistant melanoma cells

Project description:Expression data of BRAF inhibitor resistant melanoma cells

| PRJNA471347 | ENA

Expression Proteomics of BRAF Inhibitor Resistance in Melanoma Cell Lines

Project description:To investigate mechanisms of resistance to BRAF inhibitor therapy in melanoma, BRAF mutant cell lines have been chronically exposed to BRAFi to create phenotypes with acquired drug resistance. Expression proteomics is used to examine the differences between naive and drug-resistant cells.

2016-12-13 | PXD004342 | Pride

Expression of BRAF inhibitor resistant colon cancer lines

2012-09-15 | GSE34299 | GEO